Among the six collected datasets, we observed significantly higher TMB in responders of NSCLC and melanoma samples who received anti-CTLA4 blockade therapy (Figure 1C) but not in anti-PD1 treated melanoma samples. The gene discussed is CTLA4; the disease is melanoma.